Alphatec Holdings, Inc. filings document the reporting record of a spine-focused medical technology company. Its Form 8-K disclosures include quarterly and annual operating results, surgical and EOS revenue commentary, non-GAAP profitability measures, preliminary financial information and related press-release exhibits.
The company’s regulatory filings also cover material financing agreements, including senior secured credit facilities, revolving borrowing capacity, term-loan arrangements and references to convertible senior notes. Proxy and governance filings document director elections, board composition, executive and director compensation, equity awards, committee matters and other shareholder voting disclosures.
Pelizzon David R reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings director David R. Pelizzon reported a new equity award and existing indirect holdings. On June 10, 2026, he was granted 32,012 restricted stock units, each representing a contingent right to one share of Alphatec common stock. These units vest on the earlier of the next annual meeting of stockholders or his death or resignation, with pro-rata vesting based on days served if vesting is triggered by death or resignation.
Following the grant, Pelizzon directly holds 378,839 shares of common stock. Separately, 10,395,045 shares are held by Squadron Capital LLC, where he is one of two members of the managing committee. He may be deemed a beneficial owner of those shares but expressly disclaims beneficial ownership except for his pecuniary interest.
Demski David M reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings, Inc. director David M. Demski received an equity grant of 32,012 restricted stock units (RSUs). The award was effective on June 10, 2026 and represents a contingent right to receive the same number of Alphatec common shares at vesting.
The RSUs vest on the earlier of the next annual meeting of stockholders or Demski’s death or resignation. In the case of death or resignation, vesting is pro‑rated based on days served out of 365. Following this grant, Demski directly owns 431,635 shares of Alphatec common stock.
Berkowitz Mortimer III reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings director Mortimer Berkowitz III received an equity award of 32,012 restricted stock units (RSUs) on June 10, 2026. The RSUs were granted at no cash cost and each unit represents a contingent right to receive one share of Alphatec common stock.
The RSUs vest on the earlier of the next annual meeting of stockholders or the director’s death or resignation, with pro‑rata vesting in those latter cases based on days served out of 365. Following this grant, Berkowitz directly holds 650,062 shares of common stock, and the filing also reports indirect holdings through several 2016 family trusts and by his spouse, with beneficial ownership of those indirect positions expressly disclaimed except for his pecuniary interest.
Alphatec Holdings, Inc. held its 2026 annual meeting of stockholders on June 10, 2026, where stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, making both plans effective upon approval.
Stockholders also elected seven directors for one-year terms, ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of named executive officers. The meeting had 153,702,057 common shares outstanding as of the record date, with a quorum of 118,373,608 shares represented.
Alphatec Holdings, Inc. director Keith Valentine bought 135,000 shares of Common Stock in open-market transactions. The purchases occurred on May 7, 8, and 11, 2026 at weighted average prices around $7.00–$7.55 per share, increasing his direct holdings to 232,271 shares.
Footnotes explain that two of the trades were executed as multiple transactions within price ranges of $7.48–$7.50 and $7.52–$7.55 per share, with full trade-level details available on request.
Alphatec Holdings reported Q1 2026 revenue of $192.1 million, up 14% from $169.2 million a year earlier, driven by higher procedure volume and broader adoption of its spine surgery portfolio. Net loss narrowed to $33.9 million from $51.9 million as litigation expenses fell sharply.
Operating loss improved to $22.6 million versus $44.3 million, while interest expense increased due to the 0.75% Convertible Senior Notes due 2030. Cash and cash equivalents were $139.9 million and operating cash flow was modestly positive at $1.3 million.
Total debt included $405.0 million of 2030 convertible notes, $63.3 million of 2026 convertible notes, a $200.0 million Braidwell term loan and a $15.1 million revolving credit balance. After quarter-end, Alphatec replaced the Braidwell and MidCap facilities with a new $175.0 million term loan and $125.0 million revolver from JP Morgan maturing in 2031.
Alphatec Holdings, Inc. reported strong first-quarter 2026 growth and refinanced its debt with an inaugural syndicated bank facility. The new $175 million Term Loan A and $125 million revolver, led by JPMorgan and TD Securities, replace prior term loan and ABL facilities and extend maturities to 2031. At closing, the facility bears interest at SOFR plus 275 basis points and is expected to cut annual interest expense by more than $6 million, with over $35 million of potential savings over its life.
For the quarter ended March 31, 2026, total revenue reached $192 million, up from $169.2 million, with surgical revenue of $178 million growing 17% year over year on 21% case volume growth. GAAP gross margin was 71% and non‑GAAP gross margin 72%. GAAP operating expenses were $159 million, yielding a GAAP net loss of $33.9 million, or $0.22 per share, while non‑GAAP net income was roughly breakeven at $0.4 million.
Non‑GAAP adjusted EBITDA rose to $20.7 million, an 11% margin and a 460‑basis‑point expansion year over year. The company ended the quarter with $140 million in cash and reaffirmed 2026 surgical revenue guidance of about $805 million, while trimming EOS revenue to $77 million. It now targets total 2026 revenue of approximately $882 million, 15% growth, adjusted EBITDA of about $134 million (15% margin), and at least $20 million of free cash flow.
Alphatec Holdings, Inc. is soliciting proxies for its 2026 Annual Meeting on June 10, 2026, where stockholders will elect seven directors, ratify Deloitte & Touche LLP, and vote on new 2026 equity incentive and employee stock purchase plans plus an advisory say‑on‑pay proposal.
The record date is April 15, 2026, with 153,702,057 common shares outstanding, each entitled to one vote without cumulative voting. The proxy describes board and committee structure, executive leadership, ownership of major holders, and a pay‑for‑performance program tied to revenue growth and equity‑based incentives.